ArticleEuropean journal of rheumatology2021
Tofacitinib-induced remission simultaneously in arthritis and vitiligo.
Article in European journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Tofacitinib as a Promising Therapeutic Option for Vitiligo: A Systematic Review.Clinical, cosmetic and investigational dermatology · 2026Review
- Vitiligo: Ruxolitinib and Other Oral Treatment Options Beyond Ruxolitinib.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2025Review
- Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis.Dermatology and therapy · 2025Review
- Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.Journal of clinical medicine · 2023Review
- Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.International journal of molecular sciences · 2021Review
- Updates and new medical treatments for vitiligo (Review).Experimental and therapeutic medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.